TranspareRx Corporation encompasses a team of proven industry leaders who all share a passion to deliver better price transparency and savings right into the hands of millions of Americans needing help in understanding their prescription costs and available savings on their rising out-of-pocket prescription costs and benefits.• Spearheaded initial growth by establishing strategic commercial partnerships• Drove hands-on delivery of business contracts for initial revenue and impactful results• Provided strategic direction to technology team to evolve and address market needs• Supported board and investor updates as well as closed follow-on fundraising

Start-up focused on drug device combinations including AUVI-Q (epinephrine auto-injector)• Led the identification and evaluation of several drug assets for acquisition, licensing, and co-promotion. Developed and applied strategic screening criteria for pipeline creation and evaluation. Performed due diligence and financial valuations for several term sheet submissions. Negotiated and implemented co-promotion partnership with Optinose and expansion into Canada via licensing.• Launched a new medical device (injection technology) business with focus on partnering with pharmaceutical companies and government entities.• Drove the launch strategy and commercialization for two drugs, AUVI-Q and EVZIO. Responsibilities included leading sales force incentive compensation strategy, business analytics reporting and analysis, co-pay program management, mail-order hub and distribution set-up, related training, and development of access marketing materials.• Developed an innovative pharmaceutical retail channel strategy by establishing a key partnership with the 2nd largest retail pharmacy chain.• Designed and implemented a pharmaceutical channel strategy for significant savings by converting full buy-down fulfilment to a consignment program while maintaining volume.• Defined the analytics strategy and initiated the internal organizational capability build out. Developed new linkages of IMS data for more granular insight of payer coverage. Redesigned sales reports to enhance focus and drive accountability for better performance management.

No. 2 global packaging company including dispensing systems for beauty & personal care• Led 7 direct reports and 13 shared reports with over $150MM in sales and achieved additional growth through share capture.• Rebuilt the sales team and enhanced capabilities for key account strategy and value-selling.Latin America Strategy Director ’11-’14• Created and executed the transformation strategy of beauty plastics packaging division.• Performed successful exit of folding carton division.• Developed pipeline and valuation of acquisition candidates in corrugated packaging.

Boutique strategy consulting firm focused on growing and unlocking value at Fortune 500Created practical recommendations, including detailed implementation plans, to accelerate shareholder value growth for clients. Led case teams to develop a granular understanding of the sources and drivers of economic profit growth, a prioritized agenda, and economically differentiated strategies with differential allocation of resources• Optimized sales force targeting and frequency for a top 10 pharma by determining high profit physicians with responsiveness to detailing, yielding a 2-3% share increase within 6 months• Enhanced the marketing strategy for a top 10 pharma by optimizing the mix with a $60M increase in investment for 200% ROI in Direct-to-Consumer and non-personal physician marketing tactics such as eDetails, mobile alerts, and physician CRM• Developed a point of view on relative costs to competitor to formulate key manufacturing and R&D strategies for a top medical diagnostic device manufacturer• Defined a growth strategy for $100M annual economic profit impact that leverages superior forestry value creation combined with an integrated value chain advantage for a Brazilian subsidiary of a Fortune 500 forestry, paper, & packaging firm

Boutique strategy consulting firm focused on growing and unlocking value at Fortune 500Manager ’06-’08; Consultant ’04-‘06Advised the executive suite of Fortune 500 firms on top-of-mind issues such as strategic growth, value-based management, and organizational design• Defined the international M&A strategy, vis-a-vis an adjacent market “chessboard” for a pipeline of 8 targets requiring $6B in total capital for a Fortune 20 medical & pharma firm• Created a new and differentiated business model to offer an integrated patient safety solution ($40B market) to the hospital clients of a large manufacturer of basic medical supplies• Provided the strategic rationale and valuation of divestiture scenarios for a Fortune 20 manufacturer and distributor of medical products • Defined the external growth pipeline (10 targets across 3 emerging markets) for a top infant nutrition player by prioritizing the intersection of attractive geographies and product markets